Find
News Releases
= add release to Briefcase
| All Releases | |||
|---|---|---|---|
 |
New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA Sep 18, 2007 |
11.2 KB |
|
|
CHICAGO, Sept 18, 2007 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C., today announced that the investigational antibiotic ceftobiprole was as effective as commonly used combination therapy in treating patients with complicated skin infections caused by a broad spectrum of bacteria. Ceftobipr... |
|||
|
New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias Sep 18, 2007 |
11.7 KB |
|
|
CHICAGO, Sept 18, 2007 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C., today announced that the investigational antibiotic doripenem was found to clinically cure 81% of patients with nosocomial pneumonia (NP), and 68% of patients with ventilator-associated pneumonia (VAP) in studies comparing... |
|||
|
FDA Approves LEVAQUIN® Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis Sep 17, 2007 |
12.0 KB |
|
|
Raritan, NJ – September 17, 2007 – The U.S. Food and Drug Administration (FDA) has approved the use of the five-day, once-daily regimen of LEVAQUIN® (levofloxacin) 750 mg I.V. and oral, for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). 1 This latest approval is... |
|||
|
Largest Study To Date Finds Drug-Eluting Stents And Bare-Metal Stents Yield Similarly Low Mortality Rates Sep 13, 2007 |
10.8 KB |
|
|
Warren, NJ (September 13, 2007) – A network meta-analysis of 38 randomized controlled trials encompassing more than 18,000 patients found that the mortality risks associated with drug-eluting stents and bare-metal stents are similarly low. This analysis, the largest of its kind to date comparing drug-eluting stents (the CYPHER® Sirolimus-... |
|||
|
Ortho Biotech Reiterates Confidence in PROCRIT® (Epoetin alfa) Safety and Efficacy When Used According to Label Sep 12, 2007 |
48.0 KB |
|
|
Gaithersburg, MD (September 11, 2007) – As the Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) and Drug Safety and Risk Management Advisory Committee (DSRMAC) meet today to discuss questions related to erythropoiesis-stimulating agents (ESA's), Ortho Biotech reiterates its position on the follo... |
|||
|
Ortho Biotech Reiterates Confidence in PROCRIT® (Epoetin alfa) Safety and Efficacy When Used According to Label Sep 11, 2007 |
47.8 KB |
|
|
GAITHERSBURG, MD, September 11, 2007 -- As the Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) and Drug Safety and Risk Management Advisory Committee (DSRMAC) meet today to discuss questions related to erythropoiesis-stimulating agents (ESA's), Ortho Biotech reiterates its position on the following ... |
|||
|
Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease Sep 5, 2007 |
11.7 KB |
|
|
VIENNA, Austria, Sept 05, 2007 /PRNewswire via COMTEX News Network/ -- Four analyses of three-year follow-up data showed that the CYPHER(R) Sirolimus-eluting Coronary Stent may be considered an appropriate alternative to bypass surgery in patients with blockages in two or more coronary arteries (multivessel disease). The analyses were presented thi... |
|||
|
Johnson & Johnson to Participate in Bear Stearns 20th Annual Healthcare Conference Sep 4, 2007 |
6.0 KB |
|
|
NEW BRUNSWICK, N.J., Sept 04, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson will participate in the Bear Stearns Healthcare Conference on Tuesday, September 11th at The Grand Hyatt Hotel in New York City. William C. Weldon, Chairman, Board of Directors and Chief Executive Officer, will represent the Company in a session s... |
|||
|
Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent Sep 4, 2007 |
10.8 KB |
|
|
MIAMI LAKES, Fla., Sept 04, 2007 /PRNewswire via COMTEX News Network/ -- In an extensive analysis of clinical trials known as a meta-analysis, the CYPHER(R) Sirolimus-eluting Coronary Stent was associated with significantly lower risks of blood clots and the need for reintervention compared to the Taxus Stent out to 30 months after an angioplasty p... |
|||
|
Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety Sep 3, 2007 |
12.0 KB |
|
|
VIENNA, Austria, Sept 03, 2007 /PRNewswire via COMTEX News Network/ -- Clinical investigators at the European Society of Cardiology Congress 2007 (ESC Congress 2007) reported today that the CYPHER(R) Sirolimus-eluting Coronary Stent continued to provide clinical benefits compared to a bare metal stent in the E-SIRIUS Trial out to five years of foll... |
|||
|
FDA Approves RISPERDAL® to Treat Adolescents With Schizophrenia and Children and Adolescents With Bipolar Mania Aug 22, 2007 |
9.8 KB |
|
|
Titusville, NJ (August 22, 2007) -- The U.S. Food and Drug Administration (FDA) today approved RISPERDAL® (risperidone) for the treatment of schizophrenia in adolescents ages 13-17 and for the short-term treatment of bipolar mania associated with manic or mixed episodes of bipolar I disorder in children and adolescents ages 10-17. ... |
|||
|
Johnson & Johnson Statement on Civil Complaint Against The American National Red Cross and Commercial Licensees Aug 8, 2007 |
6.6 KB |
|
|
NEW YORK, Aug 08, 2007 (BUSINESS WIRE) -- Johnson & Johnson has great respect for the relief work of the American Red Cross (ARC) and over the decades has consistently supported the organization through cash donations, product donations and employee volunteering. The Company remains committed to supporting their mission through its philanthropic ef... |
|||
|
Johnson & Johnson Plans to Improve Overall Cost Structure, While Continuing to Invest in Opportunities for Sustained Profitable Growth Jul 31, 2007 |
11.7 KB |
|
|
NEW BRUNSWICK, N.J., July 31, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson today announced initiatives that are expected to generate pre-tax, annual cost savings of $1.3-$1.6 billion for 2008 in an effort to improve its overall cost structure and ensure continued profitable growth in the years to come. The company will a... |
|||
|
Ortho-McNeil, Inc., Settles Patent Infringement Litigation Against Par/Kali Jul 19, 2007 |
7.6 KB |
|
|
Raritan, NJ (July 19, 2007) – Ortho-McNeil, Inc., announced today that it settled its patent litigation against Par Pharmaceutical Companies, Inc., and its subsidiaries, Par Pharmaceutical, Inc., and Kali Laboratories, Inc., generic drug manufacturers, regarding their infringement of the Ortho-McNeil patent for ULTRACET® (tramadol/ace... |
|||
|
New Drug Application for Investigational HIV Treatment TMC125 Submitted to U.S. Food and Drug Administration Jul 18, 2007 |
9.3 KB |
|
|
YARDLEY, Pa., July 18 /PRNewswire/ -- Tibotec Pharmaceuticals Ltd. today announced the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) for TMC125 (etravirine), an investigational non- nucleoside reverse transcriptase inhibitor (NNRTI), being studied for use with other antiretroviral (ARV) agents as a treatme... |
|||
|
Johnson & Johnson Reports 2007 Second-Quarter Results: Sales Increase of 13.2% and EPS increase of 10.5% Versus a Year Ago; Excluding Special Charges in 2006, EPS increased 7.1%* Jul 17, 2007 |
26.9 KB |
|
|
NEW BRUNSWICK, N.J., July 17, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson today announced second-quarter sales of $15.1 billion, an increase of 13.2% as compared to the second quarter of 2006. Operational growth was 10.8% and currency contributed 2.4%. Domestic sales were up 9.0%, while international sales increased 18.... |
|||
|
FDA Approves First Gene-Based Test To Detect The Spread Of Breast Cancer Into Lymph Nodes Jul 17, 2007 |
10.3 KB |
|
|
Warren, NJ (July 16, 2007) – Veridex, LLC, a Johnson & Johnson company, has announced U.S. Food and Drug Administration (FDA) approval of the first intra-operative and gene-based test to detect the spread of breast cancer into the lymph nodes. The GeneSearch™ Breast Lymph Node (BLN) Assay can detect the spread of cancer into the lymp... |
|||
|
Johnson & Johnson to Host Analyst Conference Call on Second-Quarter Results Jul 11, 2007 |
6.9 KB |
|
|
NEW BRUNSWICK, N.J., July 11, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson will host a conference call for financial analysts at 8:30 a.m. EDT on Tuesday, July 17, 2007, to review second-quarter results. Dominic Caruso, Vice President, Finance and Chief Financial Officer, and Louise Mehrotra, Vice President, Investor Rel... |
|||
|
Johnson & Johnson Announces $10 Billion Share Repurchase Program Jul 9, 2007 |
8.1 KB |
|
|
NEW BRUNSWICK, N.J., July 9, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson today announced that its Board of Directors has approved a share repurchase program, authorizing the Company to purchase up to $10 billion of the corporation's shares of common stock. "This share repurchase program is consistent with our strate... |
|||
|
Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery Jul 8, 2007 |
11.3 KB |
|
|
Geneva, Switzerland (8 July, 2007) -- Late-breaking Phase III clinical trial data presented today at the XXI International Society on Thrombosis and Haemostasis (ISTH) Congress demonstrate that once-daily rivaroxaban achieved superior efficacy in the prevention of venous thromboembolism (VTE) in patients undergoing knee replacement surgery in a ... |
|||
= add release to Briefcase
